Download Image
    
Share
  
Post
MIB-626 for COVID-19
1 study with 39 patients
Hospital Icon Control
Hospital Icon MIB-626 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 MIB-626 studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -156% Mortality -156% RCTs -156% Late -156% FavorsMIB-626 Favorscontrol
MIB-626 is an oral formulation of β-nicotinamide mononucleotide (NMN), a small molecule NAD+ precursor that may restore host NAD+ levels depleted during SARS-CoV-2 infection. Recent:
Pencina.
Jun 18
 Pencina et al., FASEB BioAdvances, doi:10.1096/fba.2025-00014 Oral MIB‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID‐19 and Acute Kidney Injury: A Randomized Controlled Trial
156% higher mortality (p=1) and 18% improved recovery (p=0.71). RCT 42 hospitalized patients with COVID-19 and acute kidney injury (AKI) showing no clinical benefit with MIB-626 (β-nicotinamide mononucleotide) treatment. The study found that 1.0g of MIB-626 twice daily safely and significantly raised ..